UVEAL MELANOMA

This study tests a drug called tebentafusp in people with a specific type of eye cancer (uveal melanoma) that has spread to other parts of the body and has not been treated yet. The drug works by helping the immune system attack cancer cells. Researchers will also use a blood tes…

This study tests whether combining two drugs—olaparib and pembrolizumab—can shrink or control advanced uveal melanoma, a rare eye cancer that has spread. About 37 adults with this condition will receive the treatment. The goal is to see how many patients respond and how long the …

This early-stage trial tests a new drug called NN3201 in people with advanced cancers that have a protein called c-Kit. The drug is designed to deliver a toxic payload directly to cancer cells. The main goals are to check safety and find the right dose. About 67 adults with speci…

This study tests a drug called darovasertib given before standard surgery for people with a rare eye cancer called uveal melanoma that hasn't spread. The goal is to see if the drug can prevent vision loss and help patients keep their eye instead of needing it removed. About 520 p…

This study tests a new drug called belzupacap sarotalocan (bel-sar) for people with small eye cancers or suspicious spots that could turn into cancer. The drug is activated by a special laser to target and destroy cancer cells while sparing healthy tissue. About 100 participants …

This early-phase study tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to find a safe dos…

This study follows 15 people with choroidal melanoma who are already in a larger Phase 3 trial. Researchers will ask them to fill out surveys about their quality of life over 15 and 24 months. The goal is to understand how the disease and its treatment affect daily living, not to…

This study looks at how the liver's immune system responds to a chemotherapy drug called melphalan, given directly to the liver through a procedure called Percutaneous Hepatic Perfusion (PHP). It involves 10 people with uveal melanoma that has spread to the liver. The goal is to …

This study aims to find new genes that may increase the risk of uveal melanoma, a rare eye cancer. Only 20% of inherited cases are explained by known genes, so researchers will analyze DNA from 50 patients to discover new ones. The goal is to improve genetic testing and surveilla…

This study follows 700 people with uveal melanoma (a rare eye cancer) who have a high chance of the cancer returning. Researchers will collect blood samples to look for biomarkers that could signal liver metastases early. The goal is to see if personalized follow-up based on each…